Introduction - Gene therapy is a medical intervention based on the modification of the genetic material of living cells. Currently, gene therapy is restricted in application to somatic cells.
Zhaohui Peng
Advertisement
Dr. Zhaohui Peng is the chairman, chief executive officer, and founder of Shenzhen SiBiono GeneTech Co., Ltd., Langshen Road, Shenzhen Hi-Tech Industrial Park, Shenzhen, China, 0755.2696.8818, fax: 0755.2696.8808, sbn@sibiono.com; www.sibiono.com.
Articles by Zhaohui Peng
In October 2003, Shenzhen SiBiono GeneTech made history by becoming the first company approved to market a gene therapy medication. China's State Food and Drug Administration (SFDA) approved Gendicine for treatment of head and neck squamous cell carcinoma (HNSCC). SiBiono believes that continued clinical trials will prove Gendicine to be effective as a wide-spectrum anticancer agent.
Advertisement
Latest Updated Articles
- Points to Consider for Human Gene Therapy and Product Quality Control State Food and Drug Administration of China
Published: May 1st 2004 | Updated:
The Genesis of Gendicine: The Story Behind the First Gene TherapyPublished: May 1st 2004 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
3
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
4
